Search results for "P.O.S"

showing 10 items of 5765 documents

Psychiatric and behavioural symptoms and the use of psychotropic medication in Special Care Units and Regular Units in Norwegian nursing homes

2008

Background:  In a number of countries Special Care Units (SCUs) have been established to meet the particular needs of patients with dementia. The criteria for SCUs are poorly defined and often not met. Aim:  To assess the frequency distributions of dementia, psychiatric and behavioural symptoms and the use of psychotropic medication in SCUs and Regular Units (RUs) across different regions. Methods and material:  By means of a structured interview, comprising the Neuropsychiatric Inventory, the Clinical Dementia Rating Scale and Lawton’s Physical Self-maintenance scale, a representative sample of 1163 nonselected nursing home patients was assessed. In addition, information was collected from…

medicine.medical_specialtyClinical Dementia RatingMEDLINEBehavioral SymptomsNorwegianAlzheimer DiseaseHomes for the AgedHumansMedicineDementiaEthics MedicalPsychiatryAgedPsychotropic DrugsNorwaybusiness.industryPublic Health Environmental and Occupational HealthHealth services researchmedicine.diseaselanguage.human_languageNursing HomesPsychotic DisordersStructured interviewlanguageAlzheimer's diseasebusinessNursing homesScandinavian Journal of Caring Sciences
researchProduct

Erythropoietin in Traumatic Brain Injury: An Answer Will Come Soon

2015

Traumatic brain injury (TBI) is a major cause of morbidity and mortality in the United States. It is estimated that each year TBIs are associated with 1.1 million emergency department visits, 235,000 hospitalizations, and 50,000 deaths (1). Despite improvements in medical interventions, there are still no neuroprotective agents available to counteract secondary or delayed damage to the traumatically injured human brain or to promote its repair. TBI encompasses heterogeneous etiologic, anatomical, and molecular patterns of injury that exhibit different propensities to cause cerebral damage. Without careful consideration of individual injuries, the results of therapeutic trials remain difficu…

medicine.medical_specialtyClinical Trials as Topicbusiness.industryTraumatic brain injurySettore MED/27 - NeurochirurgiaMedicine (all)Neuroprotective AgentRecombinant Proteinmedicine.diseaseRecombinant ProteinsEpoetin AlfaNeuroprotective AgentsErythropoietinBrain InjuriesBrain InjurieReceptors ErythropoietinMedicineHumansSurgeryNeurology (clinical)businessIntensive care medicineErythropoietinmedicine.drugHuman
researchProduct

Pharmacological investigation into the effects of histamine and histamine analogues on guinea-pig and rat colon in vitro.

1986

The effects of histamine and specific histamine agonists has been examined on isolated longitudinal colon strips of guinea-pig and rat. Histamine and 2-pyridyl-ethylamine but not 4 methylhistamine produced a concentration-related contractile response in the guinea-pig colon. The H1-antagonist clemizole antagonized competitively the effect of histamine but the H2-antagonist ranitidine did not modify the dose-response curve to histamine in the guinea-pig colon. Atropine, hexamethonium, prazosin and propranolol failed to modify the contractile response to histamine. Tone induced with KCl in guinea-pig isolated colon was not modified by histamine agonists even in tissues pretreated with clemizo…

medicine.medical_specialtyColonGuinea PigsHistamine AntagonistsHistamine H1 receptorIn Vitro TechniquesHistamine agonistPotassium Chloridechemistry.chemical_compoundHistamine receptorHistamine H2 receptorInternal medicinemedicineAnimalsHistamine H4 receptorPharmacologyMethylhistaminesMuscle SmoothRats Inbred StrainsClemizoleRatsEndocrinologychemistryReceptors Histamine4-MethylhistamineHistamineResearch ArticleHistamineMuscle Contraction
researchProduct

Identification of α2-adrenoceptors and non-adrenergic idazoxan binding sites in rabbit colon epithelial cells

1990

alpha 2-Adrenoceptors are possibly involved in the regulation of the hydroelectrolytic flux across the digestive mucosa. As no data are available concerning the existence of these receptors in colon epithelial cells, we aimed to investigate the existence of alpha 2-adrenoceptors in this tissue using tritiated antagonists. [3H]Yohimbine and [3H]rauwolscine were not usable to label colonic alpha 2-adrenoceptors because of their very high level of non-specific binding. In contrast, the methoxy derivative of idazoxan, [3H]RX821002, appeared a convenient radioligand for the purpose. [3H]RX821002 bound with high affinity (KD = 6.2 +/- 0.8 nM) to a single population of non-interacting sites (Bmax …

medicine.medical_specialtyColonRauwolscinePopulationAlpha (ethology)Imidazoline receptorIn Vitro TechniquesBinding CompetitiveEpitheliumDioxaneschemistry.chemical_compoundIdazoxanInternal medicinemedicineRadioligandAnimalsBinding siteReceptoreducationAdrenergic alpha-AntagonistsPharmacologyeducation.field_of_studyBinding SitesEpithelial CellsReceptors Adrenergic alphaMolecular biologyKineticsEndocrinologychemistryRabbitsIdazoxanmedicine.drugEuropean Journal of Pharmacology
researchProduct

On the purinergic system in rat duodenum : existence of P1and P2receptors on the smooth muscle

1990

In rat duodenum, in vitro, in the presence of atropine and guanethidine, ATP administration caused a tetrodotoxin-insensitive relaxation followed by a rebound contraction. A similar response was obtained also after electrical field stimulation (EFS) of non-adrenergic, non-cholinergic (NANC) nerves. alpha, beta-methylene-TP and theophylline antagonized the response to ATP, but they failed to affect the noradrenaline- and EFS-induced relaxation. These results suggest that P1 and P2 receptors are present in rat duodenum, but their activation is not responsible for the inhibitor effects due to the NANC nerves.

medicine.medical_specialtyContraction (grammar)DuodenumPhysiologyMuscle RelaxationIn Vitro TechniquesBiologydigestive systemBiochemistryAdenosine TriphosphateTheophyllineInternal medicinemedicineAnimalsTheophyllineReceptorGuanethidinePurinergic receptorReceptors PurinergicMuscle SmoothElectric StimulationRatsAtropineElectrophysiologymedicine.anatomical_structureEndocrinologyDuodenummedicine.drugArchives Internationales de Physiologie et de Biochimie
researchProduct

Different muscarine receptors mediate the prejunctional inhibition of [3H]-noradrenaline release in rat or guinea-pig iris and the contraction of the…

1989

To investigate the muscarine receptor type mediating inhibition of [3H]-noradrenaline release from the isolated rat and guinea-pig iris we have determined the potency of antimuscarinic drugs to antagonize the methacholine-induced inhibition of [3H]-noradrenaline overflow evoked by field stimulation (3 Hz, 2 min). The prejunctional apparent affinities were compared with those obtained for postjunctional muscarine receptors mediating the methacholine-induced contraction of the isolated rabbit iris sphincter muscle. Prejunctional apparent affinity constants of pirenzepine (6.67), himbacine (8.51), methoctramine (7.92), 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP, 8.00), hexahydro-d…

medicine.medical_specialtyContraction (grammar)Iris sphincter muscleIrisIn Vitro TechniquesBiologyGuinea pigNorepinephrinechemistry.chemical_compoundPiperidinesInternal medicineMuscarinic acetylcholine receptormedicineAnimalsMethacholine CompoundsNeurotransmitterReceptorPharmacologyMuscarineMuscle SmoothRats Inbred StrainsGeneral MedicineReceptors MuscarinicElectric StimulationRatsKineticsmedicine.anatomical_structureEndocrinologychemistrySphincterRabbitsMuscle ContractionNaunyn-Schmiedebergs Archives of Pharmacology
researchProduct

The Sources of Ca2+ for Muscarinic Receptor-induced Contraction in the Rat Ileum

1996

Abstract The contractile responses obtained by activation of different muscarinic receptor subtypes in the longitudinal muscle of the rat ileum and especially the responses of this muscle to acetylcholine in a Ca2+-free medium have been investigated. In Ca2+-containing solution, acetylcholine elicited similar concentration-dependent contractile responses in the duodenum, jejunum and ileum strips of the rat intestine. The response to a maximal concentration of the agonist (1 μM) consisted of a rapid phasic response followed by a slower tonic one. Nifedipine completely relaxes or inhibits the sustained response and only partially diminishes the phasic one, which suggests that the phasic contr…

medicine.medical_specialtyContraction (grammar)NifedipinePharmaceutical ScienceIn Vitro TechniquesMuscarinic AgonistsBiologyTonic (physiology)chemistry.chemical_compoundIleumInternal medicineMuscarinic acetylcholine receptormedicineMethoctramineAnimalsRats WistarPharmacologyMuscle SmoothPirenzepineCalcium Channel BlockersReceptors MuscarinicPirenzepineAcetylcholineRatsAtropineEndocrinologychemistryCalciumFemalemedicine.symptomAcetylcholineMuscle Contractionmedicine.drugMuscle contractionJournal of Pharmacy and Pharmacology
researchProduct

Facilitatory and inhibitory muscarine receptors on the rat phrenic nerve: effects of pirenzepine and dicyclomine

1988

Neuronal transmitter stores of the rat phrenic nerve were labelled by an incubation with [3H]choline. Release of [3H]acetylcholine was elicited either by a short (100 pulses, 5 Hz) or by a long (1500 pulses, 5 or 25 Hz) period of electrical nerve stimulation. Pirenzepine and dicyclomine enhanced transmitter release evoked by the short stimulation period. Both antagonists reduced transmitter release evoked by the long stimulation period. Pirenzepine reduced transmitter release at low concentrations (1 nmol/l) whereas a higher concentration was necessary for the enhancing effect; the opposite pattern was found for dicyclomine. A low concentration of oxotremorine (10 nmol/l) enhanced and a hig…

medicine.medical_specialtyCyclohexanecarboxylic AcidsNeuromuscular JunctionDicyclomineStimulationIn Vitro TechniquesSynaptic TransmissionDicyclominechemistry.chemical_compoundInternal medicineMuscarinic acetylcholine receptormedicineAnimalsEvoked PotentialsPharmacologyMuscarineChemistryRats Inbred StrainsMuscarinic acetylcholine receptor M2PirenzepineGeneral MedicineMuscarinic acetylcholine receptor M1Receptors MuscarinicPirenzepineAcetylcholineRatsPhrenic NerveEndocrinologyAcetylcholinemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Splenic Marginal Zone Lymphoma: French Registries Population-Based Treatment and Survival Analyses (2002-2014)

2020

Background. Splenic Marginal Zone Lymphoma (SMZL) is a rare indolent B-cell lymphoma characterized by a massive splenomegaly and a moderate lymphocytosis. There is no standard of care for SMZL so far. The treatment is indicated if constitutional symptoms, massive splenomegaly and/or cytopenia, after a watch and wait period that is highly variable. Rituximab with or without chemotherapy, chemotherapy, and splenectomy are valid treatment approaches. Our objectives were to describe the characteristics of the patients with SMZL retrospectively collected from a French population database, to analyze the treatments received in first line (Tt1) and in second line (Tt2) in term of efficacy, and to …

medicine.medical_specialtyCytopeniaLymphocytosisbusiness.industryConstitutional symptomsmedicine.medical_treatmentImmunologySplenectomyCell BiologyHematologymedicine.diseaseBiochemistryLymphomaInternal medicinemedicineRituximabSplenic marginal zone lymphomaStage (cooking)medicine.symptombusinessmedicine.drugBlood
researchProduct

Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110)

2016

Abstract Background: Although ruxolitinib (RUX) reduces constitutional symptoms and splenomegaly in myelofibrosis (MF) therapy options for anemia are limited. In our prior MPNSG-0109 trial of pomalidomide (POM) in MF with cytopenia, anemia responses were reported in 14% and 29% of subjects receiving POM 0.5 mg/d and 2 mg/d, respectively (Schlenk RF et al., ASH 2013, abstract #2822). We designed a phase-Ib/-II combination study of RUX plus POM to evaluate synergistic effects in subjects with anemia and splenomegaly (MPNSG-0212 trial, NCT01644110; Stegelmann et al., ASH 2015, abstract #826). Study Design: Primary endpoints are response rate after 12 treatment cycles (28 days each) according t…

medicine.medical_specialtyCytopeniaRuxolitinibbusiness.industryAnemiaConstitutional symptomsImmunologyCell BiologyHematologyPomalidomidemedicine.diseaseBiochemistrySurgeryTransplantation03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineCohortMedicineDecompensationbusiness030215 immunologymedicine.drugBlood
researchProduct